Skip to content

A breath of fresh air

Improving the quality of life for patients with chronic respiratory diseases.

We are a clinical-stage biopharmaceutical company committed to developing oral drugs for chronic respiratory diseases, focusing on the high unmet need of COPD patients.

EpiEndo Pharmaceuticals

A semi-virtual company, headquartered in Iceland with staff in Iceland, Sweden, Denmark and the UK

EpiEndo Pharmaceuticals was founded on the knowledge that azithromycin reduces exacerbations of COPD and other respiratory diseases, effects that go beyond its antibacterial properties. However, when used chronically it promotes the development of antimicrobial resistance (AMR), which is one of the greatest global healthcare risks according to the World Healthcare Organisation (WHO).

EpiEndo Pharmaceuticals is developing a non-antibiotic macrolide, glasmacinal (previously known as EP395), which aims to expand the therapeutic options for chronic respiratory diseases beyond inhaled bronchodilators and corticosteroids with an oral treatment for respiratory diseases.

A Promising Solution for COPD Patients

COPD is the third largest cause of death globally, causing irreversible airflow obstruction.

Exacerbations of chronic respiratory diseases are mainly caused by viruses, bacteria and airborne irritants that must overcome several respiratory defence barriers and the adaptive immune system before they are able to cause infection or cause damage. 

Glasmacinal has the potential to become a unique and impactful treatment option for COPD patients with its host defense response and anti-inflammatory properties.

4.8trn
global economic burden of COPD by 2030
3rd
COPD is leading cause of death globally
20bn+
COPD therapeutic market size by 2026

About glasmacinal in respiratory diseases

Glasmacinal was developed to retain the beneficial properties of macrolides but without exerting antimicrobial activity. It is an oral anti-inflammatory drug that also enhances the host defense response and is expected to be able to be taken long-term without risking the development of antimicrobial resistance.

Treatment of COPD patients with glasmacinal has the potential to be an impactful addition to current therapy via reduced severity, frequency and duration of exacerbations and hospitalisation. EpiEndo is committed to improving the quality of life of COPD patients whilst reducing the high society & economic burden of the disease.

Our new class of oral drugs, known as Barriolides™, have the potential to be first-in-class oral therapies for COPD and other chronic respiratory diseases.

Striving for a healthier future for patients with chronic respiratory disease. We are working to transform lives of COPD patients by enhancing the host defense response to inhaled pathogens with our first-in-class drug, glasmacinal

Our Team

Dedicated Professionals

Our team of professionals is committed to making a difference in the lives of respiratory disease patients.
Chief Executive Officer
Chief Financial Officer
Chief Medical Officer
Chief Operating Officer
Head of Research
Chairman of the Board
Board Member
Board Member
Board Member
Board Member
SAB
SAB
SAB
SAB
SAB
SAB
SAB
SAB
SAB

News & Events

26 Mar 2025
Start of follow-on clinical LPS challenge study with glasmacinal (EP395)
EpiEndo Pharmaceuticals has started a second clinical LPS challenge study with lead asset, glasmacinal (EP395).
17 Dec 2024
EP395 receives INN name recognizing first-in-class drug status
EpiEndo Pharmaceuticals has received an INN (International Non-proprietary Name or generic name) from the World Health Organisation for its lead clinal drug candidate. EP395 has received the INN name glasmacinal.
18 Sep 2024
CEO, Maria Bech, to present at Access China Partnering Forum
Maria Bech, CEO of EpiEndo Pharmaceuticals will be presenting at the YAFO Capital Access China Partnering Forum on 24, 25 and 27 September 2024.
15 Aug 2024
EpiEndo to present three posters at ERS Congress 2024
EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutic addressing chronic respiratory diseases, will be presenting three posters showcasing clinical and preclinical data on lead asset EP395 in chronic respiratory diseases at the European Respiratory Society (ERS) Congress 2024 in Vienna, Austria.
Sustainability

EpiEndo's Commitment to a Better Future

We are committed to sustainability and to minimizing our environmental impact and we are working towards formalizing our ESG policies. We measure ourselves against the United Nations Sustainable Development Goals and have implemented internal goals and policies that align with these goals.

Our key pillars

Ensure healthy lives and promote well-being for all at all ages

EpiEndo aims to improve the quality of life of people with chronic respiratory diseases.

Promote inclusive and sustainable economic growth, employment and decent work for all

EpiEndo is committed to having an inclusive work culture with a healthy balance between work and private life.

Build resilient infrastructure, promote sustainable industrialization and foster innovation

EpiEndo, through its collaborative way of working, will continue to innovate and expand the life-science industry in Iceland.

Ensure sustainable consumption and production patterns

EpiEndo works towards responsible consumption and production internally and externally.

Our values

At EpiEndo, we are dedicated to conducting our business with integrity and upholding the highest ethical standards. Our code of conduct sets the standard for our employees, partners, and suppliers, and outlines our commitment to ethical behavior, compliance with laws and regulations, and respect for the rights and dignity of all individuals. Our code of conduct reflects our values and our commitment to conducting business with the highest level of professionalism and ethical standards.